Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey

Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had been treated with Pola-BR in the named patient program from March 2018 to Apr...

Descripción completa

Detalles Bibliográficos
Autores principales: Dal, Mehmet Sinan, Ulu, Bahar Uncu, Uzay, Ant, Akay, Olga Meltem, Beşışık, Sevgi, Yenerel, Mustafa Nuri, Çelik, Serhat, Kaynar, Leylagül, Yücel, Orhan Kemal, Deveci, Burak, Sönmez, Mehmet, Mehtap, Özgür, Beköz, Hüseyin Saffet, Sunu, Cenk, Salim, Ozan, Ulaş, Turgay, Kartı, Sami, Altuntaş, Fevzi, Ferhanoğlu, Burhan, Tuğlular, Tülin Fırat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676783/
https://www.ncbi.nlm.nih.gov/pubmed/36401621
http://dx.doi.org/10.1007/s00277-022-05052-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676783/
https://www.ncbi.nlm.nih.gov/pubmed/36401621
http://dx.doi.org/10.1007/s00277-022-05052-x

Ejemplares similares